黑色素瘤手术干预的减少
本文综述了黑色素瘤手术方式的演变:前哨淋巴结活检(SLNB)可能因缺乏总生存获益及生物标志物(如CP-GEP)的应用而变得多余,广泛局部切除(WLE)切缘已从5 cm降至现今的1–2 cm。新辅助治疗优于辅助治疗使治疗性淋巴结清扫(TLND)减少,未来手术干预可能显著减少。
要点
- WLE切缘已从5 cm降至现今的1–2 cm。
- pT2或更低肿瘤中97%患者无法从WLE获益。
- CP-GEP可分层高风险与低风险疾病并辅助治疗决策。
核心结论
- 黑色素瘤手术干预即将在未来数年显著减少,SLNB可能很快过时并被原发灶标准CP-GEP检测替代。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- WLE切缘已从前哨淋巴结活检时代的5 cm降至现今的1–2 cm。
- 近期研究显示WLE标本中残留肿瘤细胞频率低,pT2或更低肿瘤中97%患者无法从WLE获益。
- 完全切除的原发黑色素瘤队列的临床结局似乎不劣于接受WLE者。
- CP-GEP等生物标志物可分层高风险与低风险疾病并做出治疗决策,尤其在临床I/II期黑色素瘤中使SLNB largely redundant。
- III期辅助治疗缺乏明确总生存获益,SLNB需重新考虑;IIB/C期SLNB对辅助抗PD1治疗决策冗余。
关键数值与推荐
- CP-GEP可用于临床I/II期黑色素瘤的风险分层与治疗决策。
- pT2或更低肿瘤中97%患者无法从WLE获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Melanoma surgery has evolved from elective lymph node dissection (ELND) to sentinel lymph node biopsy (SLNB) and wide local excision (WLE) margins have come down from 5 cm to nowadays 1 - 2 cm. Recent studies have illustrated the low frequency of residual tumour cells in WLE specimen, particularly for pT2 or lower tumours, where 97 % of patients cannot benefit from WLE. Moreover, a cohort of completely excised primary melanomas did not seem to have inferior clinical outcomes to those who did undergo WLE. Biomarkers, such as clinicopathological gene expression profilers (CP-GEP), can stratify high- and low-risk disease and make therapy decisions, in particular in clinical stage I/II melanoma and make sentinel lymph node biopsy (SLNB) largely redundant. Also SLNB needs to be reconsidered due to the lack of a clear overall survival benefit for adjuvant therapy in stage III. Moreover SLNB is redundant in stage IIB/C for decision making on adjuvant anti-PD1 therapy. Moreover the superiority of neo-adjuvant to salvage patients with macroscopic stage III over adjuvant therapy leads to sharp reduction of therapeutic lymph node dissections (TLND). Overall, the major impact of current developments is that SLNB might soon become obsolete and may be replaced by standard CP-GEP testing of the primary for clinical management, reduction of surgical interventions and simplification of follow up schedules in low risk patients. Thus, we are on the eve of a significant reduction in surgical interventions for melanoma that will come in the upcoming years.
引用
- van Akkooi ACJ, Eggermont AMM. Reduction in surgical interventions in melanoma. Eur J Cancer. 2025. PMID: 40175256. doi:10.1016/j.ejca.2025.115376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。